Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been observed, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongxu, Lin, Jianzhen, Yang, Xu, Long, Junyu, Bai, Yi, Yang, Xiaobo, Mao, Yilei, Sang, Xinting, Seery, Samuel, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480748/
https://www.ncbi.nlm.nih.gov/pubmed/31014381
http://dx.doi.org/10.1186/s13045-019-0730-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480748/
https://www.ncbi.nlm.nih.gov/pubmed/31014381
http://dx.doi.org/10.1186/s13045-019-0730-9

Ejemplares similares